Lupus nephritis

American Journal of the Medical Sciences

Volumn 337, Issue 6, 2009, Pages 451-460

  Singh, Sandeep ^a   Saxena, Ramesh ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Lupus nephritis; Renal; SLE; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BELATACEPT; BELIMUMAB; CALCINEURIN INHIBITOR; CD40 LIGAND; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPRATUZUMAB; ETANERCEPT; FC RECEPTOR IIA; GLUCOCORTICOID; IDEC 31; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; RIPLIZUMAB; RITUXIMAB; SM ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROGENESIS; B LYMPHOCYTE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COOMBS TEST; CORONARY BLOOD VESSEL; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE CLASSIFICATION; DISEASE MARKER; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; ELECTRON MICROSCOPY; ETHNIC AND RACIAL GROUPS; FOLLOW UP; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOADSORPTION; IMMUNOFLUORESCENCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LABORATORY TEST; LEUKOCYTE COUNT; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MEDICAL SOCIETY; MICROSCOPY; MONOTHERAPY; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; URINE SEDIMENT; WORLD HEALTH ORGANIZATION; ARTICLE; UNITED STATES;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS NEPHRITIS; PLASMAPHERESIS; UNITED STATES;

EID: 67650257937     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181907b3d     Document Type: Article

References (97)

1. Appel GB, Radhakrishnan J, D'Agati V. Secondary glomerular disease. In: Barry M Brenner, editor. The kidney, 8th ed. Philadelphia (PA): Saunders; 2007. p. 1067-1148
2. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-424
3. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993;72:113-124
4. Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, et al. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993;2:303-312
5. Wallace DJ, Podell TE, Weiner JM, et al. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982;72:209-220
6. Masi AT, Kasslow RA. Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum 1978;21:480-484
7. Nossent HC, Henzen-Logmans SC, Vroom TM, et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 1990;33:970-977
8. Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002;112:726-729 (Pubitemid 34655662)
9. Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904-914
10. Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999;78:148-166
11. Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188-1195 (Pubitemid 27186545)
12. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526-1533 (Pubitemid 37255038)
13. Austin HA. Clinical evaluation and monitoring of lupus kidney disease. Lupus 1998;7:618-621 (Pubitemid 29008228)
14. Rodby RA, Rohde RD, Sharon Z, et al. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995;26:904-909
15. Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964;63:537-550
16. McCluskey RT. Lupus nephritis. In: Sommers SC, editor. Kidney pathology decennial 1966-1975. East Norwalk (CT): Appleton-Century-Crofts; 1975. p. 435-450
17. Churg J, Sobin LH. Renal disease: classification and atlas of glomerular disease. Tokyo: Igaku-Shoin; 1982.
18. Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases, 2nd ed. New York (NY): Igaky-Shoin; 1995.
19. Austin HA III, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-695
20. Schwartz MM, Lan SP, Bernstein J, et al. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 1993;21:374-377
21. Fiehn C, Hajjar Y, Mueller K, et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003;62:435-439 (Pubitemid 36469735)
22. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250 (Pubitemid 38140764)
23. Furness PN, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis - a UK-wide study. Am J Surg Pathol 2006;30:1030-1035 (Pubitemid 44264954)
24. Yokoyama H, Wada T, Hara A, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004;66:2382-2388
25. Botto M. Links between complement deficiency and apoptosis. Arthritis Res 2001;3:207-210
26. Casciola-Rosen L, Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997;6:175-180 (Pubitemid 27102045)
27. Herrmann M, Voll RE, Zoller OM, et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-1250 (Pubitemid 28313427)
28. Seligman VA, Suarez C, Lum R, et al. The Fcgamma receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis Rheum 2001;44:618-625 (Pubitemid 32234620)
29. Bernstein KA, Valerio RD, Lefkowith JB. Glomerular binding activity in MRL lpr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex. J Immunol 1995;154:2424-2433
30. Shlomchik MJ, Madaio MP. The role of antibodies and B cells in the pathogenesis of lupus nephritis. Springer Semin Immunopathol 2003;24:363-375 (Pubitemid 36683394)
31. Van Bruggen MC, Walgreen B, Rijke TP, et al. Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol 1997;27:1564-1569 (Pubitemid 27254851)
32. Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006;439:851-855 (Pubitemid 43255703)
33. Davies KA, Robson MG, Peters AM, et al. Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:1028-1038
34. Frank MM, Hamburger MI, Lawley TJ, et al. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1979;300:518-523 (Pubitemid 9167825)
35. Frank MM, Lawley TJ, Hamburger MI, et al. NIH conference: immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med 1983;98:206-218
36. Haseley LA, Wisnieski JJ, Denburg MR, et al. Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. Kidney Int 1997;52:1375-1380
37. Norsworthy P, Theodoridis E, Botto M, et al. Overrepresentation of the Fcgamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. Arthritis Rheum 1999;42:1828-1832 (Pubitemid 30257746)
38. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998;199:265-285
39. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-1070 (Pubitemid 27386289)
40. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998;279:1052-1054 (Pubitemid 28113310)
41. Dai C, Liu Z, Zhou H, et al. Monocyte chemoattractant protein-1 expression in renal tissue is associated with monocyte recruitment and tubulo-interstitial lesions in patients with lupus nephritis. Chin Med J (Engl) 2001;114:864-868 (Pubitemid 33611948)
42. Perez de Lema G, Maier H, Nieto E, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001;12:1369-1382 (Pubitemid 32666320)
43. Alexopoulos E, Seron D, Hartley RB, et al. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990;37:100-109 (Pubitemid 20023773)
44. Park MH, D'Agati V, Appel GB, et al. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986;44:309-319 (Pubitemid 17178104)
45. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999;92:211-218 (Pubitemid 29184885)
46. Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42:46-50.
47. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-1162
48. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-980 (Pubitemid 38269274)
49. Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-557
50. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131 (Pubitemid 34894769)
51. Ponticelli C, Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 1998;7:635-638 (Pubitemid 29008231)
52. El Hachmi M, Jadoul M, Lefebvre C, et al. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003;12:692-696 (Pubitemid 37173666)
53. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-257 (Pubitemid 32799338)
54. Houssiau FA, N'Zeusseu Toukap A, Depresseux G, et al. Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol 1998;37:448-453 (Pubitemid 28372203)
55. Jardinet D, Lefebvre C, Depresseux G, et al. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 2000;39:389-392 (Pubitemid 30307324)
56. Boumpas DT, Austin HA III, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-369
57. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1992;19:473-479
58. Austin HA III, Boumpas DT, Vaughan EM, et al. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620-1628
59. Moroni G, Ventura D, Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004;43:28-36. (Pubitemid 38049432)
60. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308. (Pubitemid 37229465)
61. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619 (Pubitemid 16132725)
62. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002. (Pubitemid 34303812)
63. Fraenkel L, Bogardus S, Concato J. Patient preferences for treatment of lupus nephritis. Arthritis Rheum 2002;47:421-428 (Pubitemid 34856132)
64. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
65. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-1084
66. Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002;115:705-709 (Pubitemid 34594285)
67. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-2228 (Pubitemid 41697285)
68. Appel GB, Dooley MA, Ginzler EM, et al. Mycophenolate mofetil compared with intravenous cyclophosphamide as induction therapy for lupus nephritis: Aspreva Lupus Management Study (ALMS) results. J Am Soc Nephrol 2007;18:47A.
69. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-2406 (Pubitemid 37542988)
70. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-3167 (Pubitemid 37409327)
71. Jones DS, Barstad PA, Feild MJ, et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995;38:2138-2144
72. Strand V, Aranow C, Cardiel MH, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12:677-686 (Pubitemid 37173664)
73. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-2480
74. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-7368
75. Lambotte O, Durbach A, Kotb R, et al. Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol 2005;64:73-77 (Pubitemid 40975069)
76. Available at: http://www.researchwikis.com/Systemic-Lupus-Erythematosus- Marketing-Research.
77. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
78. Ding C, Foote S, Jones G. B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs 2008;22:239-249 (Pubitemid 351969831)
79. Greenwald RJ, Boussiotis VA, Lorsbach RB, et al. CTLA-4 regulates induction of anergy in vivo. Immunity 2001;14:145-155
80. Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-3169 (Pubitemid 39371992)
81. Cui TG, Hou FF, Ni ZH, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi 2005;44:672-676
82. Austin HA III, Boumpas DT, Vaughan EM, et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544-550
83. Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994;24:159-171 (Pubitemid 24249053)
84. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039-2046 (Pubitemid 37220309)
85. Braun N, Erley C, Klein R, et al. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 2000;15:1367-1372 (Pubitemid 30705921)
86. Favre H, Miescher PA, Huang YP, et al. Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 1989;9(suppl 1):57-60.
87. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-1379
88. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-3174 (Pubitemid 41447099)
89. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005;29:219-228 (Pubitemid 43041673)
90. Euler HH, Schroeder JO, Harten P, et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37:1784-1794 (Pubitemid 24371881)
91. Wallace DJ, Goldfinger D, Pepkowitz SH, et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 1998;13:163-166 (Pubitemid 29029275)
92. Danieli MG, Palmieri C, Salvi A, et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002;17:72-77 (Pubitemid 34809554)
93. Huang DF, Tsai ST, Wang SR. Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci 1994;15:283-288
94. Pfueller B, Wolbart K, Bruns A, et al. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001;44:1962-1963 (Pubitemid 32758245)
95. Stummvoll GH, Aringer M, Smolen JS, et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005;64:1015-1021 (Pubitemid 40909515)
96. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;13:168-176 (Pubitemid 38478643)
97. Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-173 (Pubitemid 36091660)